Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

IJMDC. 2018; 2(January 2018): 38-46


Anti-IL-17 markedly inhibited the in vitro granuloma induced by Schistosoma mansoni soluble egg antigen.

Asmaa Ezz, Irene S. Gmail, Fatma Elzahraa H. Salem, Rabab Salama, Soad Nady.




Abstract

IL-17 is a proinflammatory cytokine produced by T helper cells and is involved in the recruitment of white blood cells during the formation of granuloma induced by Schistosoma eggs. The aim of the present study was to examine the formation of in vitro granuloma induced by Schistosoma mansoni soluble egg antigen (SEA) after neutralization of IL-17 using Anti-IL-17 antibody. Peripheral blood mononuclear cells (PBMCs) were isolated from 20 S. mansoni monoinfected, 50 S. mansoni/Hepatitis C virus (HCV) coinfected patients and 25 healthy individuals. The isolated PBMCs were used for in vitro granuloma induction using S. mansoni SEA conjugated polyacrylamide beads. Different concentrations of Anti-IL-17 (0.5, 1, 2 or 4 ng/ml) were added to the cultured granuloma at the first day then the sizes of granuloma were assessed by granuloma index (GI) after 3, 7 or 14 days. Results revealed that, Anti-IL-17 at a concentration of 2 ng/ml optimally reduced the GI of the granuloma formed using PBMCs isolated from S. mansoni monoinfected, S. mansoni/HCV coinfected patients or healthy individuals after all the experimental time intervals. In conclusion, IL-17 blocking with the neutralizing Anti-IL-17 antibody promotes a marked reduction in the sizes of granuloma induced by S. mansoni SEA.

Key words: Peripheral blood mononuclear cells, Th-17 cells, IL-17 cytokine, Schistosoma mansoni, granuloma, Anti-IL-17 antibody.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.